# Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

> **NCT02923921** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 567 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Pegilodecakin
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT02923921
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2019-09-09
- **Final completion:** 2020-03-05
- **Target enrollment:** 567 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02923921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02923921, "Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02923921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*